The tweet was deleted by the author.
But we saved everything 🙂.
Candel Therapeutics, Inc. announced the release of new extended follow-up data from its phase 3 trial evaluating aglatimagene besadenovec (CAN-2409) in patients with localized prostate cancer.
The results, presented at the #AUA26 meeting, provide fresh insights into the efficacy and durability of its investigational immunotherapy. The company continues to advance CAN-2409 as a potential treatment for prostate cancer, attracting attention from both clinicians and investors. Further details are available through the official presentation link provided by Candel Therapeutics, Inc.
View post on X Loading...
Earlier this year, Candel Therapeutics CEO called for prioritizing patient engagement to accelerate drug discovery during a panel at BioEquityEurope. The company also marked a leadership milestone as Chief Regulatory Officer Susan Stewart was named among RAPSorg 50 for 50, recognizing regulatory excellence. These developments reflect Candel's recent corporate and industry recognition.